Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Depreciation & Amortization (CF) (2016 - 2025)

Apyx Medical (APYX) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $221000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 55.63% year-over-year to $221000.0, compared with a TTM value of $655000.0 through Dec 2025, up 9.35%, and an annual FY2025 reading of $655000.0, up 9.35% over the prior year.
  • Depreciation & Amortization (CF) was $221000.0 for Q4 2025 at Apyx Medical, up from $164000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $247000.0 in Q2 2022 and bottomed at $132000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $186950.0, with a median of $194000.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) crashed 38.87% in 2023, then soared 55.63% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $229000.0 in 2021, then fell by 11.79% to $202000.0 in 2022, then dropped by 24.75% to $152000.0 in 2023, then dropped by 6.58% to $142000.0 in 2024, then skyrocketed by 55.63% to $221000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for APYX at $221000.0 in Q4 2025, $164000.0 in Q3 2025, and $132000.0 in Q2 2025.